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Nineteen monoclonal antibodies which bind to native dystrophin in the plasma membrane of frozen muscle sections were obtained using a recombi- 
nant fusion protein as immunogen. On Western blots of normal mouse muscle extracts, the antibodies bind specifically to a 400000 M, protein 
which is absent from dystrophic mouse (mdr) muscle. At least four distinct epitopes have been identified by cleavage mapping methods. Although 
the fusion protein contained 25% of the human dystrophin sequence (Cy~rl~-Asp~‘~~; M, IOSOOO), most of the monoclonal antibodies (15 out of 
19) recognize a single fragment of M, 27 500. 
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1. INTRODUCTION 
Dystrophin is a muscle membrane protein which is 
absent, reduced or altered as a result of mutation in the 
Duchenne muscular dystrophy (DMD) gene or its 
homologue in the mouse [l]. The large size of 
dystrophin (427 kDa) and its low abundance (< 0.01% 
of the total muscle protein) are hindrances to the isola- 
tion of intact, native protein for structure/fun~ion 
studies. 
Monoclonal antibodies against defined regions of 
dystrophin provide a means of studying its structure 
and function, interactions with other proteins and the 
nature of the partial gene products produced in some 
patients carrying deletions in the dystrophin gene [Z]. 
Predictions from the sequence suggest a structural pro- 
tein on the inner face of the membrane, consisting of a 
25repeat, rod-like, triple-helical domain separating an 
N-terminal actin-binding domain from two C-terminal 
domains, one of which is rich in cysteine [3]. Polyclonal 
antisera have been prepared against two helical regions 
using fusion protein immunogens [I] and a monoclonal 
antibody against he beginning of the helical region has 
been prepared from a synthetic peptide [4]. We now 
describe the production of monoclonal antibodies 
which can identify at least four distinct regions of 
dystrophin in the proposed helical region. 
cloned into the EcoRI site of pEX2 (Genofit Ltd), an expression vec- 
tor containing the la& gene [7], and the recombinant plasmid 
(pEX2 : Cf23) was digested with PstI or BamHI plus &/II to produce 
deletion derivatives pEX2 : Cf23b and pEX2 : Cf23c respectively 
(fig. la). The two plasmids thus derived were introduced into E. co& 
POP2136 to enable expression of the corresponding &galactosidase 
fusion proteins, designated LacZ-108kD and LacZ-42kD respectively 
(fig.lc,e). POP2136 (pEX2: Cf23b) cells were grown at 30°C to log 
phase and then incubated for 1.5 h at 44°C to induce expression of the 
fusion protein. Inclusion bodies were released from the cell pellet by 
sonication at 4°C in TNE buffer (50 mM NaCl, 1 mM EDTA, 50 mM 
Tris-HCl pH 8.0) and collected by centrifugation at 10000 x g for 10 
min. The pellet was boiled in 2 ml of SDS buffer (2% SDS, 50 mM 
Tris-HCl. pH 6.8) with 5% 2-mercaptoethanol (2-ME). After cen- 
trifugation at 100000 x g for 20 min, the supernatant was subjected 
to gel filtration (85 x 1.2 cm; Ultrogel AcA34, LKB) in SDS buffer 
with 1 mM 2-ME. Fractions containing lacZ-108kD without major 
cont~in~ts were identified by SDS-PAGE and pooled. The protein 
was precipitated with ethanol (50% v/v), redissolved in 0.3 ml 8 M 
urea in PBS, diluted to 3 M urea and incubated at 37°C for 30 min. 
No attempt was made to remove DNA or residual traces of SDS. An 
emulsion in complete Freund’s adjuvant was used to immunise &lb/c 
mice (ca. 100 rg), with boosts 1 month later in incomplete adjuvant 
and twice in PBS, 2,3 or 4 days before fusion, after a rest period of 
l-2 months. Sera were tested 10 days after the second injection. Fu- 
sions were performed [8] with myeloma lines SpZ/O, NSO and NSl 
and screened by ELISA [9], using microtiter plates coated with either 
lacZ-108kD or pEX2 ,&galactosidase alone. Hybridoma culture 
supernatants were further tested by immunofluorescence microscopy 
before cloning to homogeneity (at least twice) by limiting dilution. 
2.2. ~mmuno~uor~cenee microscopy 
2. METHODS 
Sections (7 pm) of human or mouse muscle frozen in isopentane 
were mounted on glass slides and stored at - 70°C. Bound antibody 
was detected with FITC-labelled rabbit anti-mouse Ig (DAKO), using 
a Leitz Dialw microscope with epifluorescence optics and Ilford HP5 
film was exposed for 30 s [lo]. 
A 4.3 kb dystrophin cDNA fragment designated Cf23 [5,6] was 
2.1. Preparation of intmunogen and monoclonal antibodies 
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2.3. Western blotting 
To minimise degradation, fresh minced muscte was dropped into 4 
vols of boiling extraction buffer (IOYo SDS, 10% EDTA, 5% 2-ME, 
10% glycerol, 50 mM Tris-HCI pH 6.7) [4], homogenised immediate- 
ly in a Silverson blender, boiled again for 3 min and centrifuged (IO0 
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Fig.1. Production of recombinant fusion proteins and identification of monoclonal antibody binding sites by NTCB cleavage at Cys residues. 
K, 20 min). After SDS-PAGE on 4-12370 gradient gels [l] (10 x 12 
cm wide), protein bands were transferred electrophoretically (BioRad 
Transblot) to nitrocellulose at 100 mA overnight in 25 mM Tris, 192 
mM glycine. Blots were developed with monoclonal antibody culture 
supematants (l/100) as described pieviously [8]. 
3. RESULTS 
Fig. 1. shows (a) dystrophin cDNA and the restriction 
fragments derived from it, (b) the domain structure of 
dystrophin predicted from its primary sequence [3] and 
(c) the fl-galactosidase fusion protein (lacZ-108kD) 
which we prepared from cDNA encoding part of the 
rod-like helical repeat region. Mice were immunised 
with partially purified, solubilised lacZ-108kD for 
monoclonal antibody production. From one mouse, 
136 out of 587 hybridoma-containing wells (23% of the 
total) produced antibody recognising lacZ-108kD, but 
not 1acZ alone, in ELISA. Those which bound most 
strongly and specifically to the plasma membrane of 
frozen sections of adult mouse or human muscle 
(fig.2a) were selected for cloning. Sixteen were obtained 
from this mouse and three from a second. All of the an- 
tibodies identified the same 400 kDa protein on 
Western blots of normal mouse muscle (fig.2b). None 
of the antibodies reacted with any protein in mdx 
dystrophic mouse muscle, either in frozen sections or 
Western blots (fig.2). 
For epitope mapping, we used a combination of 
nitrothiocyanobenzoic acid (NTCB) cleavage at Cys 
238 
residues [11,121, proteolytic cleavage and DNA deletion 
analysis. Incomplete digestion by NTCB produces a 
ladder of partial cleavage fragments (A, AB, ABC, etc.) 
from which each antibody selects a characteristic 
‘fingerprint’. Fig.3 shows predicted NTCB fragments 
(up to 60 kDa) for antibodies binding to fragments A-D 
(predictions for E-H or above 60 kDa are complicated 
by the fl-galactosidase contribution) alongside actual 
(4 
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Fig.2. Monoclonal antibody characterization. (a) Monoclonal an- 
tibody binding to the plasma membrane of muscle from normal 
(NOR), but not dystrophic (MDX), mouse. (b) The 400kDa protein 
present in normal mouse muscle (nor) is absent from dystrophic mus- 
cle (mdx). M, markers: myosin (205 kDa), phosphofructokinase (84 
kDa), fumarase (48 kDa). The antibodies shown belong to the ‘C’ 
epitope class (fig.ld), but all 19 antibodies gave similar results. 
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Fig.3. Epitope mapping of monoclonal ntibodies by Western blotting. The crude pellet of lacZ-108kD inclusion bodies was boiled in SDS buffer 
(FP; lanes 1,4,5,8) or cleaved with nitrothiocyanobenzoic acid (Sigma) in 5 M guanidine-HC1 as described [l l] (NTCB; lanes 2,3,6,7), separated 
on a SDS-15% polyacrylamide gel (10 x 12 cm) and blotted by diffusion [8]. The antibodies used to develop the blots were MANDYS1,16,18 
and 19, representing the 3 classes in fig.ld. Predicted NTCB fragment sizes for A. B, C and D (fig.lc) are shown alongside the actual cleavage 
products and prestained molecular weight markers (M,; up to 25.7 kDa, Gibco-BRL; 26.6-84 kDa, Sigma). The 60 kDa degradation product (lanes 
1 and 4) and the smallest NTCB fragment (lane 3), which may be derived from it, are indicated by closed and open circles respectively between 
lanes 4 and f . 
Western blots for the 3 classes of antibody. Attention 
should be paid to the pattern of fragments in the 10-40 
kDa region, rather than to the precise position of any 
one fragment, since the relationship between molecular 
weight and migration position in SDS gels often shows 
deviations of 2-3 kDa or more. The lane 2 pattern (15 
antibodies) corresponds quite closely to that predicted 
for fragment C and lanes 3 and 6 (3 antibodies) to a 
fragment D pattern, notably in the smallest predicted 
fragments (C, 27 500; D, 12 600) and the smallest frag- 
ment common to both (CD, 40000). There is no 
resemblance to the predicted A and B fragment patterns 
in this lo-40 kDa region. MANDYS19 is the only an- 
tibody which binds in ELISA to a shorter fusion protein 
(la&-42kD) containing E-H and part of D (fig.le; 
results not shown) and its NTCB fingerprint differs 
from any predicted (lane 7). This demonstrates an 
epitope within EFGH and supports an ABCD alloca- 
tion for the other 18. All 15 ‘C’ antibodies bind to a ma- 
jor degradation product in lacZ-108kD (lane I) but the 
‘EFGH’ antibody (MANDYS19; lane 8) and one of the 
3 ‘D’ antibodies (MANDYSIS; lane 5) do not, 
demonstrating aproteolytic cleavage site within ‘D’. Its 
size (60 kDa) indicates a fragment containing all, or 
nearly all, of ABC (55 kDa) and part of D (fig.le). The 
unpredicted, smallest fragment in lane 3 may also arise 
from this proteolytic cleavage within ‘D’ since only 
those ‘D’ antibodies which recognise the 60 kDa frag- 
ment bind to it. Thus, the results of three different map- 
ping techniques are internally consistent. 
4. DISCUSSION 
We have shown that monoclonal antibodies which 
detect dystrophin on both Western blots and frozen 
tissue sections bind to at least four different dystrophin 
sequences. Such antibodies could be used in a rapid test 
for specific dystrophin epitopes in those MD patients 
with an altered from of dystrophin [2]. 
The high proportion of antibodies against fragment 
C could be explained by our selection of antibodies 
which bind both to native, authentic dystrophin in sittd 
and to partially denatured recombinant dystrophin on 
ELISA plates. This might select antibodies which bind 
239 
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to accessible and denaturation-resistant epitopes. Alter- 
natively, high immunogenicity might be an intrinsic 
property of this dystrophin region. Hoffmann et al. [l] 
found that a smaller PATH fusion protein (trpE-30kD), 
containing an insert which includes part of fragment C, 
was much more immunogenic than one containing 60 
kDa from a different helical region. The presence of 
stable repeating structures could explain higher im- 
munogenicity (cf. collagen repeats [14]), since there is 
no evidence of any locally high density of amino-acid 
differences between human and mouse dystrophin to 
account for it [13] and all the antibodies cross-react 
with mouse dystrophin. The 30 kDa insert (G~u”‘~- 
Phe13”) of Hoffmann et al. [l] and fragment C 
(cys’26s -Cys”“) each contain three triple-helical 
repeats and they overlap by one complete repeat [3]. 
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